About dbv technologies - DBVTF
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.
DBVTF At a Glance
DBV Technologies SA
107 avenue de la Republique
Chatillon, Hauts-de-France 92320
| Phone | 33-1-55-42-78-78 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -146,947,000.00 | |
| Sector | Health Technology | Employees | 125 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
DBVTF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.541 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.825 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.057 |
DBVTF Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,175,576.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
DBVTF Liquidity
| Current Ratio | 3.67 |
| Quick Ratio | 3.67 |
| Cash Ratio | 3.346 |
DBVTF Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -98.169 |
| Return on Equity | -149.826 |
| Return on Total Capital | -77.156 |
| Return on Invested Capital | -141.388 |
DBVTF Capital Structure
| Total Debt to Total Equity | 12.848 |
| Total Debt to Total Capital | 11.385 |
| Total Debt to Total Assets | 9.278 |
| Long-Term Debt to Equity | 3.205 |
| Long-Term Debt to Total Capital | 2.84 |